BRAF and melanoma: Given the lack of insight into the efficacy of the CDK4/6 inhibitor monotherapy in melanomas, and the possible synergy and efficacy when combined with other inhibitors in BRAF and NRAS mutant melanomas, most of the current ongoing trials are evaluating combination CDK4/6 inhibitors with other targeted therapies [142].